Metcash Selects Coveo AI as an e-Commerce Partner

Metcash Selects Coveo AI as an e-Commerce Partner

Australia's leading wholesaler teams with Coveo and SAP to elevate product discovery, personalization and conversion, helping independent retailers make informed procurement decisions, speeding ordering, invoicing, and receiving products MONTREAL...

JVCKENWOOD Corporation Selects IFS Cloud to Modernize Global Manufacturing Operations

JVCKENWOOD Corporation Selects IFS Cloud to Modernize Global Manufacturing Operations

Driving the modernization of manufacturing and supply chain management through an AI-enabled ERP and MES platform TOKYO, March 12, 2026 /PRNewswire/ -- IFS, the leading provider of Industrial AI software, today announced that JVCKENWOOD has selected...

Manulife Selects Akka to Operationalize Agentic AI within its Enterprise AI Platform

Manulife Selects Akka to Operationalize Agentic AI within its Enterprise AI Platform

Akka to provide a secure and scalable software foundation to build trusted AI-powered business applications TORONTO and SAN FRANCISCO, March 10, 2026 /PRNewswire/ -- Manulife announced today that Akka has been selected as its latest partner...

New Zealand's Medical Assurance Society (MAS) Selects Duck Creek Technologies for Core Insurance Modernization

New Zealand's Medical Assurance Society (MAS) Selects Duck Creek Technologies for Core Insurance Modernization

Duck Creek selection supports MAS ' enterprise-wide technology transformation to enhance Member experiences, expand products and services, and improve efficiency SYDNEY, Feb. 25, 2026 /PRNewswire/ -- New Zealand's Medical Assurance Society (MAS) has...

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies. - I n NHPs, ASC36 oral tablets reduced mean body...

Nissan Selects IPfolio from Clarivate

Nissan Selects IPfolio from Clarivate

Managing IP with advanced workflow automation technology and leading data LONDON, Dec. 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Nissan Motor Co., Ltd (Nissan:...

Microsoft Selects Iron Software as Key .NET 10 Launch Partner for APAC Region, Showcasing C# Generate PDF Innovation at .NET Conf Thailand 2025

Microsoft Selects Iron Software as Key .NET 10 Launch Partner for APAC Region, Showcasing C# Generate PDF Innovation at .NET Conf Thailand 2025

Iron Software successfully hosted Microsoft-sponsored virtual event, delivering expert insights on .NET 10 migration, AI-powered development, and performance optimization to developers across Asia-Pacific. CHICAGO and CHIANG MAI, Thailand, Dec. 16,...

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9 - , 30 - , and 60-fold higher than semaglutide, tirzepatide, and retatrutide in...

Evergy Selects Kigen To Strengthen Grid Resilience Across Private and Public Networks

Evergy Selects Kigen To Strengthen Grid Resilience Across Private and Public Networks

Evergy Selects Kigen's Secure eSIM OS and eIM to Maximize Grid Reliability with Automated Failover Across Private and Public Networks KANSAS CITY, Mo. and CAMBRIDGE, England, Nov. 3, 2025 /PRNewswire/ -- Evergy, one of the largest investor-owned...

Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development

Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development

-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3 -fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91 %...

  • 1
  • 2
  • menu
    menu